Curated News
By: NewsRamp Editorial Staff
September 08, 2025
Cybin Completes Phase 2 Enrollment for Anxiety Treatment CYB004
TLDR
- Cybin's CYB004 Phase 2 completion offers investors first-mover advantage in a novel anxiety treatment market with strong patent protection and potential for significant returns.
- Cybin completed enrollment for Phase 2 study of CYB004, a deuterated DMT program using intramuscular dosing for GAD treatment, with topline data expected Q1 2026.
- CYB004 could provide effective therapy for millions with treatment-resistant anxiety, improving mental healthcare access and quality of life for those underserved.
- Cybin is developing a deuterated DMT treatment for anxiety that offers convenient dosing and represents a breakthrough in neuropsychiatry with Phase 2 data due in 2026.
Impact - Why it Matters
This development matters because Generalized Anxiety Disorder affects millions worldwide, with current treatments often proving ineffective for half of patients. The advancement of novel psychedelic-based therapies like CYB004 represents a potential paradigm shift in mental healthcare, offering hope for those who have exhausted conventional options. Successful development could lead to more accessible, effective, and convenient treatment options, potentially reducing the global burden of anxiety disorders and improving quality of life for countless individuals.
Summary
Cybin Inc., a clinical-stage neuropsychiatry company trading on the NYSE American and Cboe CA under the symbol CYBN, has achieved a significant milestone by completing enrollment in its Phase 2 study of CYB004. This proprietary deuterated dimethyltryptamine (DMT) program targets Generalized Anxiety Disorder (GAD), a condition affecting approximately 6.8 million people in the U.S., half of whom do not respond to existing treatments. Interim CEO Eric So emphasized that this achievement supports Cybin's mission to deliver effective therapies, highlighting CYB004's potential for convenient intramuscular dosing and strong patent protection. Topline data from this groundbreaking study are expected in the first quarter of 2026.
As part of the Dynamic Brand Portfolio at IBN, PsychedelicNewsWire serves as a specialized communications platform covering all aspects of psychedelics and the latest sector developments. The company is also advancing CYB003, a deuterated psilocin analog in Phase 3 studies for major depressive disorder with Breakthrough Therapy Designation from the FDA, along with a research pipeline of investigational 5-HT-receptor focused compounds. Founded in 2019 and operational across Canada, the United States, the United Kingdom, and Ireland, Cybin represents a pioneering force in mental healthcare innovation through its novel drug development approach.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cybin Completes Phase 2 Enrollment for Anxiety Treatment CYB004
